Straits Times Index
3,255.14 -37.99 (-1.15%) Nikkei
37,951.46 -508.62 (-1.32%) Hang Seng
17,201.27 +372.34 (+2.21%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,519.52 -2,185.98 (-3.28%) CMC Crypto 200
1,396.32 -27.78 (-1.95%)
Novo Nordisk A/S (NVO)
After hours:
| Previous close | 128.64 |
| Open | 127.16 |
| Bid | 125.50 x 1200 |
| Ask | 125.70 x 1000 |
| Day's range | 125.35 - 127.32 |
| 52-week range | 75.56 - 138.28 |
| Volume | |
| Avg. volume | 5,036,312 |
| Market cap | 567.763B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 47.43 |
| EPS (TTM) | 2.66 |
| Earnings date | N/A |
| Forward dividend & yield | 1.37 (1.09%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | 144.57 |
ZacksNovo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
- Reuters
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
A U.S. Senate committee said on Wednesday it had launched an investigation into the prices of Novo Nordisk's diabetes and weight loss drugs Ozempic and Wegovy in the United States. Senator Bernie Sanders, chair of the Senate Committee on Health, Education, Labor and Pensions, sent a letter to Novo's CEO seeking more information on U.S. prices for the two drugs, which are higher than the prices in other countries. The committee also asked Novo if it will substantially reduce both the list price and the net price of both the drugs, and why the company was charging a higher price for the weight loss drug Wegovy than Ozempic, which contains the same compound.
Zacks4 Large Drug Stocks to Hold on to Amid Industry Challenges
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
